273 related articles for article (PubMed ID: 32518351)
1. Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.
Omizo H; Tamura Y; Morimoto C; Ueno M; Hayama Y; Kuribayashi-Okuma E; Uchida S; Shibata S
Sci Rep; 2020 Jun; 10(1):9326. PubMed ID: 32518351
[TBL] [Abstract][Full Text] [Related]
2. The Protective Effect of Febuxostat on Chronic Tacrolimus-Induced Nephrotoxicity in Rats.
Kim HS; Lim SW; Jin L; Jin J; Chung BH; Yang CW
Nephron; 2017; 135(1):61-71. PubMed ID: 27701176
[TBL] [Abstract][Full Text] [Related]
3. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress.
Tsuda H; Kawada N; Kaimori JY; Kitamura H; Moriyama T; Rakugi H; Takahara S; Isaka Y
Biochem Biophys Res Commun; 2012 Oct; 427(2):266-72. PubMed ID: 22995295
[TBL] [Abstract][Full Text] [Related]
4. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy.
Omori H; Kawada N; Inoue K; Ueda Y; Yamamoto R; Matsui I; Kaimori J; Takabatake Y; Moriyama T; Isaka Y; Rakugi H
Clin Exp Nephrol; 2012 Aug; 16(4):549-56. PubMed ID: 22350467
[TBL] [Abstract][Full Text] [Related]
5. Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model.
Lee HJ; Jeong KH; Kim YG; Moon JY; Lee SH; Ihm CG; Sung JY; Lee TW
Am J Nephrol; 2014; 40(1):56-63. PubMed ID: 25034030
[TBL] [Abstract][Full Text] [Related]
6. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
Matsuo H; Ishikawa E; Machida H; Mizutani Y; Tanoue A; Ohnishi T; Murata T; Okamoto S; Ogura T; Nishimura Y; Ito H; Yasutomi M; Katayama K; Nomura S; Ito M
Clin Exp Nephrol; 2020 Apr; 24(4):307-313. PubMed ID: 31845065
[TBL] [Abstract][Full Text] [Related]
8. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia.
Sánchez-Lozada LG; Tapia E; Soto V; Avila-Casado C; Franco M; Wessale JL; Zhao L; Johnson RJ
Nephron Physiol; 2008; 108(4):p69-78. PubMed ID: 18434753
[TBL] [Abstract][Full Text] [Related]
9. A role for uric acid in the progression of renal disease.
Kang DH; Nakagawa T; Feng L; Watanabe S; Han L; Mazzali M; Truong L; Harris R; Johnson RJ
J Am Soc Nephrol; 2002 Dec; 13(12):2888-97. PubMed ID: 12444207
[TBL] [Abstract][Full Text] [Related]
10. Xanthine Oxidase Inhibitor Febuxostat Exerts an Anti-Inflammatory Action and Protects against Diabetic Nephropathy Development in KK-Ay Obese Diabetic Mice.
Mizuno Y; Yamamotoya T; Nakatsu Y; Ueda K; Matsunaga Y; Inoue MK; Sakoda H; Fujishiro M; Ono H; Kikuchi T; Takahashi M; Morii K; Sasaki K; Masaki T; Asano T; Kushiyama A
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31546603
[TBL] [Abstract][Full Text] [Related]
11. Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.
Fahmi AN; Shehatou GS; Shebl AM; Salem HA
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):819-30. PubMed ID: 27215580
[TBL] [Abstract][Full Text] [Related]
12. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial.
Tanaka K; Nakayama M; Kanno M; Kimura H; Watanabe K; Tani Y; Hayashi Y; Asahi K; Terawaki H; Watanabe T
Clin Exp Nephrol; 2015 Dec; 19(6):1044-53. PubMed ID: 25676011
[TBL] [Abstract][Full Text] [Related]
13. Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.
Kohagura K; Satoh A; Kochi M; Nakamura T; Zamami R; Tana T; Kinjyo K; Funakoshi R; Yamazato M; Ishida A; Sakima A; Iseki K; Arima H; Ohya Y
J Hypertens; 2023 Sep; 41(9):1420-1428. PubMed ID: 37334544
[TBL] [Abstract][Full Text] [Related]
14. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
Kohagura K; Tana T; Higa A; Yamazato M; Ishida A; Nagahama K; Sakima A; Iseki K; Ohya Y
Hypertens Res; 2016 Aug; 39(8):593-7. PubMed ID: 27075830
[TBL] [Abstract][Full Text] [Related]
15. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Nishikawa T; Nagata N; Shimakami T; Shirakura T; Matsui C; Ni Y; Zhuge F; Xu L; Chen G; Nagashimada M; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S; Ota T
Sci Rep; 2020 Jan; 10(1):815. PubMed ID: 31965018
[TBL] [Abstract][Full Text] [Related]
16. Multiple-Purpose Connectivity Map Analysis Reveals the Benefits of Esculetin to Hyperuricemia and Renal Fibrosis.
Wang Y; Kong W; Wang L; Zhang T; Huang B; Meng J; Yang B; Xie Z; Zhou H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33080936
[TBL] [Abstract][Full Text] [Related]
17. Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats.
Shirakura T; Nomura J; Matsui C; Kobayashi T; Tamura M; Masuzaki H
Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):831-8. PubMed ID: 27198514
[TBL] [Abstract][Full Text] [Related]
18. Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models.
Li X; Yan Z; Tian J; Zhang X; Han H; Ye F
Ann Clin Lab Sci; 2019 Nov; 49(6):756-762. PubMed ID: 31882426
[TBL] [Abstract][Full Text] [Related]
19. Randomized, Open-Label, Cross-Over Comparison of the Effects of Benzbromarone and Febuxostat on Endothelial Function in Patients with Hyperuricemia.
Nakata T; Ikeda S; Koga S; Yonekura T; Tsuneto A; Doi Y; Fukae S; Minami T; Kawano H; Maemura K
Int Heart J; 2020 Sep; 61(5):984-992. PubMed ID: 32921665
[TBL] [Abstract][Full Text] [Related]
20. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia.
Zhang X; Wan D; Yang G; Peng Q; Wang X
Int Urol Nephrol; 2019 Dec; 51(12):2273-2283. PubMed ID: 31646459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
